异基因造血干细胞移植后人细小病毒B19感染的诊治现状  

The current status of diagnosis and treatment of human parvovirus B19 infection after allogeneic hematopoietic stem cell transplantation

作　　者：张晋 孙于谦[1] ZHANG Jin;SUN Yuqian(Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing,100044,China)

机构地区：[1]北京大学人民医院,北京大学血液病研究所,国家血液系统疾病临床医学研究中心,造血干细胞移植治疗血液病北京市重点实验室,北京100044

出　　处：《临床血液学杂志》2024年第3期222-226,共5页Journal of Clinical Hematology

基　　金：国家自然科学基金(No:8227010768);科技部重点研发计划(No:2021YFC2500300)。

摘　　要：人细小病毒B19(human parvovirus B19,HPVB19)属细小病毒科,红细胞病毒属,与多种疾病相关,是异基因造血干细胞移植后难治性贫血的重要原因之一。异基因造血干细胞移植后HPVB19感染最常见的临床表现为贫血伴网织红细胞计数下降,严重者可进展为纯红细胞再生障碍,同时可伴有白细胞和血小板减少症、皮疹、关节痛、心肌炎、肝炎、肺炎等,诊断主要依赖核酸检测。使用静脉注射免疫球蛋白与免疫抑制剂减量为有效的治疗手段。HPVB19感染预后好但复发率高。本文对异基因造血干细胞移植后HPVB19感染患者的临床特点及诊疗方案进行文献综述。Human parvovirus B19(HPVB19)belongs to the parvoviridae family,erythroparvovirus,which is responsible for a variety of human diseases and is one of the important causes of refractory anemia after allogeneic hematopoietic stem cell transplantation(allo-HSCT).The most common clinical manifestations of HPVB19 infection after allo-HSCT is anemia with decreased reticulocyte count,which can progress to pure red cell aplasia,but it also can be accompanied by leukopenia and thrombocytopenia,rash,arthralgia,myocarditis,hepatitis,pneumonia,etc.The diagnosis of HPVB19 infection mainly depends on nucleic acid testing.Intravenous immunoglobulin and immunosuppressant dose reduction are effective treatments.HPVB19 infection has a good prognosis but a high recurrence rate.This article reviews the clinical features and diagnosis and treatment of HPVB19 infection in patients after allo-HSCT.

关 键 词：人细小病毒B19 异基因造血干细胞移植 纯红细胞再生障碍 

分 类 号：R457.7[医药卫生—治疗学]